Tesamorelin + Ipamorelin + CJC-1295
Three-way GH stack.
- Sizes available
- —
- Lab certificate (COA)
- Arrives with shipment
· Research-grade only · Not for human consumption · 21+ ·
Tesa + IPA + CJC 3-way GH stack. Visceral fat cut + strong pulse.
Mechanism · Triple GH-axis blend (GHRH analog + GHRP + DAC GHRH).
Best for. Not for.
Best for
- The strongest visceral-fat cut (referencing Tesa Egrifta, FDA 2010, HIV lipodystrophy)
- Users with prior GH-stack experience who have graduated from a single Ipa+CJC protocol
- Users pursuing a 12-week cycle of fat loss and GH peak together
Not for
- Active malignancy or cancer history (downstream IGF-1 concern)
- Pregnancy or nursing
- Active type 2 diabetes or pronounced insulin resistance
- Sleep apnea untreated
- First-time GH-axis users should start with a single Ipa+CJC protocol
Mechanism, dose, ramp, risk.
- Mechanism
- Triple blend for visceral cut + GH pulse.Source · PEPVERA editorial
- Target dose
- Per protocol.Source · PEPVERA editorial
- Ramp
- 12-Week.Source · PEPVERA editorial
- Risks
- Per components.Source · PEPVERA editorial
Compared to its siblings.
Tesamorelin + Ipamorelin + CJC-1295
Tesa + IPA + CJC 3-way GH stack. Visceral fat cut + strong pulse.
Pros
- · Stronger visceral-fat cut than two-way Ipa+CJC base.
- · GH-pulse synergy absent in tesamorelin monotherapy.
Cons
- · More complex protocol than two-way Ipa+CJC blend.
- · Higher cost than simpler two-way stack.
- · No standalone FDA label; tesamorelin monotherapy has Egrifta 2010 for HIV lipodystrophy.
Ipamorelin + CJC Blend
Two-way base. Milder; the first-stack standard.
Pros
- · Simpler protocol
- · Cost-effective
Cons
- · Visceral fat effect weaker
See Ipamorelin + CJC Blend →
Tesamorelin
Tesa monotherapy. The FDA-approved indication (HIV lipodystrophy) only.
Pros
- · FDA Egrifta 2010
Cons
- · No GH-pulse synergy
See Tesamorelin →
COA per supplier
Published, in-house, or shipment-time
Each supplier declares its own HPLC floor and COA policy. The per-supplier verifier appears on the certificate page; refund and shipping terms vary by supplier and are shown on the supplier listing.
Compare 0 suppliers
No verified suppliers yet for this compound.
Direct from foundry. Slower than domestic resellers; consistency is the trade. Insulated packaging, tracked from departure to doorstep. Replacement issued on damage.
Risk
Per components. These pass with discipline. They do not pass with bravado.
Source · PEPVERA editorialDiscipline
12-Week.
Source · PEPVERA editorialWellness
Hydrate. Eat protein. Sleep eight. Hold a dose for at least two weeks before ascending.
Anti-patterns
- · Do not pair with stimulants late in the day.
- · Do not break the cycle without a planned taper.
- · Do not exceed the dose to chase a deeper sleep response.
Crisis
If the ramp triggers severe anxiety, anhedonia, or persistent gastrointestinal disturbance, stop. Resume after two weeks at half the prior dose. The discipline is the slow climb.
Week 1–2
Per protocol.
Initiation
Week 3–4
Per protocol.
Signal emerges
Week 5–8
Per protocol.
Hold
Week 9–12
Cycle review
Assess
Draw 20 units.
1 mg = 0.20 mL at 5.00 mg/mL. 10.0 doses per vial.
niche · V
Tesamorelin + Ipamorelin + CJC-1295 · 10mg